Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Brigham and Women's Hospital
Headquarters: Boston, MA, United States of America
Website: http://www.brighamandwomens.o...
Year Founded: 1980
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jul 10, 2024
Emerging Company Profile
Mestag: Attacking tumors from within
Immunology company’s lead program targets a specific fibroblast subpopulation to induce formation of tertiary lymphoid structures in solid tumors
BioCentury | Jun 28, 2024
Politics, Policy & Law
Clearest impacts of Chevron ruling will be on disputes over exclusivity, other non-science issues
Broad effect of Supreme Court decision on science-based regulation unclear
BioCentury | May 18, 2024
Discovery & Translation
Brain-penetrant AAV capsid progress at ASGCT
Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting
BioCentury | May 16, 2024
Politics, Policy & Law
Rare disease legislation clears speed bump
House subcommittee endorses pediatric voucher reauthorization, but more Democrats needed to win in Senate
BioCentury | Apr 30, 2024
Distillery Therapeutics
Targeting the lncRNA MERRICAL for diabetes-associated atherosclerosis
BioCentury | Apr 22, 2024
Regulation
Defending accelerated approval. Plus: endpoint innovation & AIM amiss: a BioCentury podcast
Why it’s wrong to conclude half of cancer accelerated approvals are useless
BioCentury | Apr 18, 2024
Editor's Commentary
Drive-by analysis of accelerated approval is intellectual malpractice
Medical journals, news publications incorrectly conclude half of cancer accelerated approvals are useless
BioCentury | Jan 23, 2024
Politics, Policy & Law
How Arnold Ventures paved the road to the IRA
And what the biopharma industry’s most effective critic wants to do next
BioCentury | Dec 12, 2023
Distillery Therapeutics
MTA depletion to overcome immunotherapy resistance in MTAP-deficient tumors
BioCentury | Dec 6, 2023
Politics, Policy & Law
Fixing the IRA’s orphan exemption
Patient groups, academics, industry propose different changes to the single-orphan exemption from Medicare price negotiation
Items per page:
1 - 10 of 420